Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 18/20 | 1.00 |
| ▸ | DAO | P14920 | 2/20 | 0.65 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.56 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.54 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18670454 | 0.76 | FEN1 (1.00) | FEN1ERCC1ERCC4CA12RNASEH1 | |
| SCHEMBL29960340 | 0.76 | FEN1 (1.00) | FEN1ERCC1ERCC4CA12RNASEH1 | |
| SCHEMBL18670378 | 0.73 | FEN1 (1.00) | FEN1 | |
| SCHEMBL18670337 | 0.72 | FEN1 (1.00) | FEN1 | |
| SCHEMBL29960854 | 0.72 | FEN1 (1.00) | FEN1DAOERCC1ERCC4CA12 | |
| SCHEMBL18670448 | 0.72 | FEN1 (1.00) | FEN1DAOERCC1ERCC4CA12 | |
| SCHEMBL18670294 | 0.72 | FEN1 (1.00) | FEN1DAOERCC1ERCC4CA12 | |
| SCHEMBL29960205 | 0.72 | FEN1 (0.59) | FEN1ERCC1ERCC4CA12RNASEH1 | |
| SCHEMBL29960132 | 0.71 | FEN1 (1.00) | FEN1ERCC5 | |
| SCHEMBL18670451 | 0.71 | FEN1 (1.00) | FEN1ERCC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108430978-B | 3-hydroxy-quinazoline-2, 4-dione derivatives and their use as nuclease modulators | 路德维格癌症研究所有限责任公司 | 2022-11-22 | — | — | CN | disclosed |
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2022-02-22 | — | — | US | disclosed |
| EP-3353154-B1 | 3-HYDROXY-7-(SULFONYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND 3-HYDROXY-PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES AND RELATED COMPOUNDS AS FLAP-ENDONUCLEASE 1 (FEN-1) INHIBITORS FOR USE IN CANCER THERAPY | LUDWIG INST FOR CANCER RES LTD (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-07-30 | — | — | US | disclosed |
| EP-3353154-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017051251-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051251-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253521-B2 | 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators | FEN1, ERCC4, XPA | FEN1 1/4885DAO 2346/4885ERCC1 7/4885 |
| US-20200237763-A1 | 3-HYDROXY-QUINAZOLINE-2,4-DIONE DERIVATIVES AND THEIR USE AS NUCLEASE MODULATORS | FEN1, ERCC4, XPA | FEN1 1/4885DAO 2346/4885ERCC1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.